Follistatin 344 vs Survodutide
Side-by-side comparison of key properties, dosing, and research.
Anabolic & IGF
Follistatin 344GLP-1 / Weight Loss Agonists
Survodutide- Summary
- Follistatin 344 is a recombinant form of the endogenous follistatin protein. It inhibits myostatin and activin — the primary negative regulators of muscle growth — potentially removing the genetic ceiling on muscle development. It is one of the most theoretically powerful anabolic compounds but is experimental with limited human data.
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Half-Life
- ~24–36 hours
- ~7 days
- Admin Route
- SubQ, IM
- SubQ
- Research
- —
- —
- Typical Dose
- 100 mcg
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- Frequency
- Once daily
- Once weekly
- Key Benefits
- Inhibits myostatin — removes muscle growth ceiling
- Significant increases in muscle mass and strength
- Reduces fat mass
- Promotes bone density
- May stimulate hair follicle cycling
- Anti-fibrotic effects in muscle tissue
- Synergistic with IGF-1 and other anabolic peptides
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Side Effects
- Muscle soreness (from rapid hypertrophy)
- Potential reproductive effects (activin inhibition)
- Unknown long-term safety profile
- Possible esophageal effects at high doses (animal data)
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Stacks With
- —
- —